CD34 and acute myeloid leukemia: Third, dose–response combinatorial assays of CCC representative drugs were carried out in order to determine viability matrices, allowing for the quantification of cumulative synergistic effects as described in Dietlein et al.,30 2015 and subsequent CCC synergistic fingerprinting of AML samples, as well as normal CD34-positive mobilized peripheral blood cell controls (Figures 5a and b).